Afanix 40 mg Tablet is an oral anticancer medication containing Afatinib, a second-generation tyrosine kinase inhibitor (TKI) used in the targeted treatment of specific lung cancers. Developed and manufactured by Beacon Pharmaceuticals Ltd. and supplied globally by Onco Solution, Afanix 40 mg reflects a modern, precision-based approach to oncology therapy. It has been formulated to address the unmet needs of patients with epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC).

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Tyrosine Kinase Inhibitor (TKI)

Description

Afanix 40 mg works by selectively inhibiting the activity of the epidermal growth factor receptor (EGFR) and ErbB family of tyrosine kinases, which play a critical role in the growth, survival, and spread of cancer cells. Afatinib forms an irreversible bond with these receptors, effectively blocking abnormal signaling pathways that drive tumor progression.

This targeted mechanism allows Afanix to specifically act on cancer cells harboring EGFR mutations, helping to slow disease progression while reducing damage to healthy tissues. As a result, Afanix 40 mg offers a more focused and effective treatment option compared to conventional chemotherapy, with improved tolerability for long-term use.

Indications

Afanix 40 mg is primarily indicated for the treatment of adult patients with:

• Metastatic or locally advanced non-small cell lung cancer (NSCLC) with confirmed EGFR mutations

Treatment should be initiated and supervised by an experienced oncology specialist.

Dosage & Administration

• The recommended dose is 40 mg once daily, taken orally.

• Afanix may be taken with or without food.

• Tablets should be swallowed whole with water and not crushed or chewed.

• Dose adjustments may be required based on individual tolerability and adverse reactions.

• Regular follow-up and clinical monitoring are essential to assess therapeutic response and manage side effects.

Benefits

Afanix 40 mg provides several clinically meaningful benefits for patients with EGFR-mutated NSCLC, including:

• Targeted inhibition of cancer cell growth and spread

• Delay in disease progression

• Improvement in overall survival outcomes

• Reduction in cancer-related symptoms such as cough, shortness of breath, and fatigue

• Enhanced quality of life through a more tolerable safety profile

Clinical evidence supports Afatinib as an effective first-line and subsequent-line therapy in appropriately selected patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Manufacturer

Beacon Pharmaceuticals Ltd. is a renowned pharmaceutical manufacturer dedicated to producing high-quality, innovative medicines. With advanced manufacturing facilities and strict quality assurance systems, Beacon Pharmaceuticals ensures that each Afanix 40 mg tablet meets international regulatory and safety standards. Their commitment to research-driven oncology solutions continues to strengthen their role in global cancer care.

Supplier

Onco Solution is a trusted global supplier of oncology medicines, ensuring reliable access to Afanix 40 mg across international markets. Through an extensive distribution network and strong logistical capabilities, Onco Solution supports healthcare providers by delivering life-saving cancer therapies efficiently and responsibly. Their focus on accessibility and accurate medical information further enhances patient care worldwide.

Conclusion

Afanix 40 mg Tablet represents a significant advancement in targeted lung cancer therapy. By combining the scientific innovation of Beacon Pharmaceuticals Ltd. with the global distribution expertise of Onco Solution, Afanix delivers a precise, effective, and patient-focused treatment option for EGFR-mutated NSCLC. As oncology continues to move toward personalized medicine, Afanix stands as a powerful example of how collaboration and innovation can improve outcomes and offer renewed hope to patients worldwide.